Stalicla signs license deal for Evgens’ SFX-01
Evgen Pharma and Stalicla sign a $165 million licensing deal for neuro development disorder SFX-01 asset
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Evgen Pharma and Stalicla sign a $165 million licensing deal for neuro development disorder SFX-01 asset
Merck's Covid-19 pill no help in reducing hospitalization or death, Astrazenaca's nasal spray too fails trial
New malaria vaccine by Oxford University has 80% efficacy
The EC has intimated Teva Pharmaceutical Industries, an Israel-based global company, of its "preliminary view" that it has breached EU antitrust rules by.
Japanese scientists develop method to detect alzheimer's in blood by measuring amyloid β build up.
A new study reveals cellular changes that take place in response to exercise and high-fat diets
New gene responsible for malfunctioning of lysosome pathways discovered by Michigan researchers
Indian drugmaker Maiden Pharma linked to 66 deaths in Gambia
Screening tests such as MCED can detect cancers early and help in quick diagnosis and treatment
HT team As the Covid-19 pandemic torments the world, scientists in the US have made a drug that brings the virus’s downfall. Chemicals.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com